Running Point Capital Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Running Point Capital Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$11K	–	210
2022 Q3	$11K	Hold	10,000	–	–	0.01%	197
2022 Q2	$17K	Hold	10,000	–	–	0.01%	191
2022 Q1	$21K	Buy	+10,000	New	+$27K	0.01%	183

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Running Point Capital Advisors's ADAP Position: Q4 2022 in Review

Running Point Capital Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2022, closing a stake of 10,000 shares — an estimated $11K sold.

Running Point Capital Advisors first reported a position in ADAP in Q1 2022 and held it in 3 quarters. The position peaked at $21K in Q1 2022. 69 funds tracked by Wall St. Rank hold ADAP as of Q4 2022.

Running Point Capital Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2022 after selling out during the quarter.
Running Point Capital Advisors sold 10,000 Adaptimmune Therapeutics shares in Q4 2022, an estimated $11K.
Running Point Capital Advisors first reported a position in Adaptimmune Therapeutics in Q1 2022 and held it in 3 quarters.
Running Point Capital Advisors's Adaptimmune Therapeutics position peaked at $21K in Q1 2022.
69 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2022.

Based on Running Point Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.